Similar Survival With Breast Conservation Therapy or Mastectomy in the Management of Young Women With Early-Stage Breast Cancer

Mahmood, Usama; Morris, Christopher G.; Neuner, Geoffrey; Koshy, Matthew; Kesmodel, Susan B.; Buras, R.; Chumsri, Saranya; Bao, Ting; Tkaczuk, Katherine; Feigenberg, Steven J.

doi:10.1016/j.ijrobp.2011.10.075

Cited by 59 publications

(40 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Six randomized controlled trials comparing mastectomy and BCT all included a low proportion of young breast cancer patients (12-23%) [44], making it hard to draw any conclusion for this subgroup. Few cohort studies restricted to young breast cancer patients have been published [2,[45][46][47][48][49], and they are limited by the inclusion of a mixture of different TNM stages, by the variety of adjuvant systemic treatments offered, and by a median follow-up time of less than 10 years. In contrast, the present study is based on an unbiased cohort (comprising almost all lymph node negative patients below 41 years treated in Denmark in the 1989-1998 period) with complete registration of incident breast cancer and complete follow-up data on LRR and mortality within 20 years.…”

Section: Discussionmentioning

confidence: 99%

Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients

et al. 2016

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients

et al. 2016

View full text Add to dashboard Cite

“…[43][44][45] However, despite higher local recurrence rates, 46,47 data suggest similar long-term outcomes for young women who undergo breast conservation compared to those who chose more extensive surgery. [48][49][50] It is therefore important to confirm whether a more aggressive surgical approach is warranted. Data from existing registries could be mined to compare lumpectomy versus mastectomy outcomes, determine whether local recurrence in YWBC 51,52 impacts overall survival, and determine the long-term morbidity and mortality for each surgical option.…”

Section: Treatmentmentioning

confidence: 99%

Breast Cancer in Young Women: Research Priorities. A Report of the Young Survival Coalition Research Think Tank Meeting

Korde

Partridge

Esser

et al. 2015

Journal of Adolescent and Young Adult Oncology

View full text Add to dashboard Cite

Breast cancer in young women is a significant issue-7% of all female breast cancer is diagnosed in women under 40 years of age. Young women with breast cancer (YWBC) face significant and unique challenges, including a higher likelihood of biologically aggressive disease and metastatic disease at diagnosis, leading to poorer prognosis, more aggressive treatment and long-term treatment-related toxicities, and unique psychosocial concerns. This article summarizes the Young Survival Coalition (YSC) Research Think Tank Meeting, held in Arlington, Virginia, in February 2013, and presents the process that led to YSC's priorities for YWBC research. The meeting's participants focused on six broad categories of investigation in which additional advancements in research on YWBC are crucial: risk factors; treatment; fertility; pregnancy-associated breast cancer; quality of life and survivorship; and metastasis. Several key themes emerged from this meeting. Researchers and advocates felt that a large-scale data registry focused on YWBC is necessary to collect quality information to guide future research for YWBC. This database should include clinical data, genomic profiling of primary tumor and metastatic sites, and an increased focus on fertility and pregnancy following breast cancer treatment. The participants also felt that more must be done to elucidate how and why YWBC develop more aggressive tumors, and to what degree treatment should be modified for young women. The discussions summarized here led to the formulation of YSC's Research Agenda, published in May 2014.

show abstract

“…However, those trials evaluated outdated chemotherapy and radiotherapy treatments, with few younger patients in their samples. The most recent trials have shown that, despite the fact that it increases the risk of local relapse, conservative surgery has no significant impact on survival 25 . Being young is no longer a contraindication to breast-conserving therapy.…”

Section: Revista Brasileira De Cancerologia 2018; 64(1): 45-53mentioning

confidence: 99%

Real-World Data Related to Non-Metastatic Breast Cancer in Young Women: Experience of a Single Institution

Souza

Nunes

Silva

et al. 2018

Rev. Brasileira.De.Cancerologia

View full text Add to dashboard Cite

Introduction: Breast cancer is the leading cause of cancer-related deaths in women aged 20-59 years. Younger women usually have more aggressive tumors and more advanced disease with larger size and axillary lymph node involvement. There have been few studies assessing the characteristics of breast cancer in very young women. Objective: Evaluate the epidemiological and clinical profile of non-metastatic very young patients with breast cancer. Method: We performed a retrospective analysis to evaluate the epidemiological and clinical profile of non-metastatic breast cancer in patients ≤ 30 years of age treated between 1993 and 2011 at the Brazilian National Cancer Institute José Alencar Gomes da Silva. We evaluated relapse-free survival (RFS) and overall survival (OS). Results: Of the 196 patients evaluated, 181 (90%) had ductal carcinoma, 79 (40%) had high-grade tumors, and 102 (52%) had hormone receptor-positive tumors. 117 patients(60%) had stage III disease at diagnosis. The median age was 29 years (range, 17-30 years). Of 185 patients who underwent surgery, 156 (84.3%) underwent total mastectomy and 171 (92%) underwent axillary lymph node dissection. 119 patients received neoadjuvant chemotherapy, and 14 patients (9.3%) underwent neoadjuvant radiotherapy. After a median follow-up of 81.5 months, 109 patients (55%) had relapsed and 81 (41%) had died. The median RFS and OS were 49.5 months and 134 months, respectively. Lymph node involvement and neoadjuvant chemotherapy were associated with shorter RFS and OS. Conclusion: Breast cancer is uncommon in young patients, especially in those ≤ 30 years of age. We found a predominance of locally advanced disease and worse prognostic pathological characteristics. Despite the aggressive treatment, our patients had worse outcomes than those reported by other authors.

show abstract

Similar Survival With Breast Conservation Therapy or Mastectomy in the Management of Young Women With Early-Stage Breast Cancer

Cited by 59 publications

References 18 publications

Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients

Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients

Breast Cancer in Young Women: Research Priorities. A Report of the Young Survival Coalition Research Think Tank Meeting

Real-World Data Related to Non-Metastatic Breast Cancer in Young Women: Experience of a Single Institution

Contact Info

Product

Resources

About